Search Results - "IIDA, Shinsuke"

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients by Kurose, Koji, Ohue, Yoshihiro, Wada, Hisashi, Iida, Shinsuke, Ishida, Takashi, Kojima, Takashi, Doi, Toshihiko, Suzuki, Susumu, Isobe, Midori, Funakoshi, Takeru, Kakimi, Kazuhiro, Nishikawa, Hiroyoshi, Udono, Heiichiro, Oka, Mikio, Ueda, Ryuzo, Nakayama, Eiichi

“…FoxP3(+) Tregs inhibit immune responses against tumors. KW-0761 is a humanized anti-human CCR4 monoclonal antibody (mAb) that has antibody-dependent cellular…”
Get full text

Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan by Suzuki, Tomotaka, Maruyama, Dai, Iida, Shinsuke, Nagai, Hirokazu

“…Abstract Multiple myeloma is a cancer of plasma cells; the incidence rate of multiple myeloma is high among older adults. Although significant advances have…”
Get full text

Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database by Handa, Hiroshi, Ishida, Tadao, Ozaki, Shuji, Mori, Asuka, Kato, Kenichi, Iida, Shinsuke

“…Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with…”
Get full text

Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab by Maeda, Yuka, Wada, Hisashi, Sugiyama, Daisuke, Saito, Takuro, Irie, Takuma, Itahashi, Kota, Minoura, Kodai, Suzuki, Susumu, Kojima, Takashi, Kakimi, Kazuhiro, Nakajima, Jun, Funakoshi, Takeru, Iida, Shinsuke, Oka, Mikio, Shimamura, Teppei, Doi, Toshihiko, Doki, Yuichiro, Nakayama, Eiichi, Ueda, Ryuzo, Nishikawa, Hiroyoshi

“…Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are…”
Get full text

Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database by Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Asuka Mori, Kenichi Kato, Shinsuke Iida

“…Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with…”
Get full text

IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma by Amanda, Stella, Tan, Tze King, Ong, Jolynn Zu Lin, Theardy, Madelaine Skolastika, Wong, Regina Wan Ju, Huang, Xiao Zi, Ali, Muhammad Zulfaqar, Li, Yan, Gong, Zhiyuan, Inagaki, Hiroshi, Foo, Ee Yong, Pang, Brendan, Tan, Soo Yong, Iida, Shinsuke, Sanda, Takaomi

“…IRF4 is a master regulator of immunity and is also frequently overexpressed in mature lymphoid neoplasms. Here, we demonstrate the oncogenicity of IRF4 in…”
Get full text

Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer by Marumo, Yoshiaki, Kusumoto, Shigeru, Masaki, Ayako, Nakashima, Takahiro, Kikuchi, Takaki, Mori, Fumiko, Komatsu, Hirokazu, Inagaki, Hiroshi, Iida, Shinsuke, Inagaki, Atsushi

“…Malignant lymphoma developing during anti-PD-1 antibody treatment is extremely rare. A 74-year-old female was admitted with left hypochondrial pain. She was…”
Get full text

A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma by Iida, Shinsuke, Sunami, Kazutaka, Minami, Hironobu, Hatake, Kiyohiko, Sekiguchi, Risa, Natsume, Kazuto, Ishikawa, Norifumi, Rinne, Mikael, Taniwaki, Masafumi

“…PIM447, a pan-proviral integration site for Moloney leukemia (PIM) kinase inhibitor, has shown preclinical activity in multiple myeloma (MM). This phase I,…”
Get full text

Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study by Takamatsu, Hiroyuki, Iida, Shinsuke, Shibayama , Hirohiko, Shibayama, Kazuhiro, Yamazaki, Hiroshi, Suzuki, Kenshi

“…Lenalidomide and dexamethasone (Rd) treatment is common for patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem-cell…”
Get full text

Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma by Ishida, Takashi, Ito, Asahi, Sato, Fumihiko, Kusumoto, Shigeru, Iida, Shinsuke, Inagaki, Hiroshi, Morita, Akimichi, Akinaga, Shiro, Ueda, Ryuzo

“…We report an adult T‐cell leukemia/lymphoma patient suffering from Stevens–Johnson Syndrome (SJS) during mogamulizumab (humanized anti‐CCR4 monoclonal…”
Get full text

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma by Tachita, Takuto, Kinoshita, Shiori, Ri, Masaki, Aoki, Sho, Asano, Arisa, Kanamori, Takashi, Yoshida, Takashi, Totani, Haruhito, Ito, Asahi, Kusumoto, Shigeru, Komatsu, Hirokazu, Yamagata, Kazufumi, Kubo, Kohmei, Tohkin, Masahiro, Fukuda, Shinsaku, Iida, Shinsuke

“…Cereblon (CRBN) is a target for immunomodulatory drugs. This study investigated the prognostic value of the expression of CRBN‐pathway genes on the clinical…”
Get full text

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia by Sekiguchi, Naohiro, Rai, Shinya, Munakata, Wataru, Suzuki, Kenshi, Handa, Hiroshi, Shibayama, Hirohiko, Endo, Tomoyuki, Terui, Yasuhito, Iwaki, Noriko, Fukuhara, Noriko, Tatetsu, Hiro, Iida, Shinsuke, Ishikawa, Takayuki, Iguchi, Daisuke, Izutsu, Koji

“…The phase II study of tirabrutinib monotherapy at a daily dose of 480 mg under fasting conditions for treatment‐naïve and relapsed/refractory Waldenström's…”
Get full text

Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries by Suzuki, Takayoshi, Ota, Yosuke, Ri, Masaki, Bando, Masashige, Gotoh, Aogu, Itoh, Yukihiro, Tsumoto, Hiroki, Tatum, Prima R, Mizukami, Tamio, Nakagawa, Hidehiko, Iida, Shinsuke, Ueda, Ryuzo, Shirahige, Katsuhiko, Miyata, Naoki

“…To find HDAC8-selective inhibitors, we designed a library of HDAC inhibitor candidates, each containing a zinc-binding group that coordinates with the…”
Get full text

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors by Fujikawa, Kaoru, Saito, Takuro, Kurose, Koji, Kojima, Takashi, Funakoshi, Takeru, Sato, Eiichi, Kakimi, Kazuhiro, Iida, Shinsuke, Doki, Yuichiro, Oka, Mikio, Ueda, Ryuzo, Wada, Hisashi

“…Introduction Regulatory T cells (Tregs) have attracted attention as a novel therapeutic target to augment the clinical efficacy of immunotherapy. We conducted…”
Get full text

Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) – a focus on healthcare resource utilization and cost by Iida, Shinsuke, Ishida, Tadao, Horimoto, Katsuhisa, Kazama, Hirotaka, Kim, Hyunchung, Crawford, Bruce, Teshima, Takanori

“…This study explored the burden associated with stem cell mobilization, with or without cyclophosphamide (CPA), in patients who intended to receive autologous…”
Get full text

Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma by Shibayama, Hirohiko, Matsumoto, Morio, Kosugi, Hiroshi, Shibayama, Kazuhiro, Yamazaki, Hiroshi, Iida, Shinsuke

“…Subcutaneous daratumumab (DARA SC; daratumumab co-formulated with recombinant human hyaluronidase PH20) is administered in ~ 5 min and demonstrates safety and…”
Get full text

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma by Maekawa, Keiko, Ri, Masaki, Nakajima, Miki, Sekine, Akihiro, Ueda, Ryuzo, Tohkin, Masahiro, Miyata, Naoki, Saito, Yoshiro, Iida, Shinsuke

“…Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to…”
Get full text

Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy by Raje, Noopur, Mateos, María-Victoria, Iida, Shinsuke, Reece, Donna

“…Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will…”
Get full text

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105) by Maruyama, Dai, Iida, Shinsuke, Machida, Ryunosuke, Kusumoto, Shigeru, Fukuhara, Noriko, Yamauchi, Nobuhiko, Miyazaki, Kana, Yoshimitsu, Makoto, Kuroda, Junya, Tsukamoto, Norifumi, Tsujimura, Hideki, Usuki, Kensuke, Yamauchi, Takahiro, Utsumi, Takahiko, Mizuno, Ishikazu, Takamatsu, Yasushi, Nagata, Yasuyuki, Ota, Shuichi, Ohtsuka, Eiichi, Hanamura, Ichiro, Suzuki, Yasuhiro, Yoshida, Shinichiro, Yamasaki, Satoshi, Suehiro, Youko, Kamiyama, Yutaro, Fukuhara, Suguru, Tsukasaki, Kunihiro, Nagai, Hirokazu

“…Among patients with PS 2–3 at study enrollment (10 patients each in both arms), the long-term PFS in Arm A also tended to be better compared with that in Arm…”
Get full text

Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy by Raje, Noopur, Mateos, María-Victoria, Iida, Shinsuke, Reece, Donna

Get full text